Description
The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to reach USD 60.7 billion by 2032, expanding at a CAGR of 6.4% during the forecast period. Incretin-based drugs primarily include GLP-1 receptor agonists and DPP-4 inhibitors, which enhance glucose-dependent insulin activity through different mechanisms. GLP-1 receptor agonists directly activate GLP-1 receptors, promoting insulin secretion, reducing glucagon release, slowing gastric emptying, and influencing appetite, while DPP-4 inhibitors extend the activity of endogenous incretin hormones by preventing their enzymatic degradation. The underlying demand base is being strengthened by the rising global prevalence of type 2 diabetes, increasing obesity rates, and the growing clinical emphasis on therapies that provide benefits beyond glycemic control. GLP-1-based therapies have gained particular commercial importance because of their ability to support weight reduction and, for selected therapies, deliver cardiovascular and kidney-related benefits. This has broadened their role from traditional diabetes management into the wider field of cardiometabolic care. At the same time, the increasing preference for non-insulin therapies is supporting the use of incretin-based medicines as initial or add-on treatment options for appropriate patients.
Technology and product innovation are further reshaping the competitive landscape. Improvements in peptide engineering, long-acting formulations, prefilled injection devices, and oral delivery technologies are addressing historical limitations associated with peptide-based therapies. Oral semaglutide has demonstrated the feasibility of delivering a GLP-1 receptor agonist through an oral formulation, while dual GIP/GLP-1 agonists such as tirzepatide have expanded the therapeutic opportunity by simultaneously targeting multiple incretin pathways. These developments are creating differentiation based on efficacy, dosing frequency, tolerability, convenience, and broader metabolic outcomes. However, market expansion remains constrained by high treatment costs, reimbursement limitations, supply considerations, adverse effects, and contraindications associated with certain therapies. Gastrointestinal tolerability is particularly relevant for GLP-1-based treatments and can influence treatment persistence. DPP-4 inhibitors continue to occupy an important position because of their established oral administration, relatively favorable tolerability profile, and suitability for patients who cannot or do not prefer GLP-1-based therapies. From a geographic perspective, North America remains the largest regional market, supported by high treatment adoption, advanced healthcare infrastructure, specialist availability, and strong commercial presence of leading pharmaceutical companies, while Asia Pacific represents the fastest-growing region due to its large and expanding diabetes population and improving access to modern therapies. Looking ahead, the market is likely to evolve toward more convenient dosing formats, oral and next-generation delivery technologies, combination therapies, expanded cardiometabolic indications, and increasingly personalized treatment pathways.
Key Highlights of the Report
• GLP-1 receptor agonists represent the leading drug type, supported by strong clinical efficacy in glucose management and increasing use in obesity and weight-management treatment.
• DPP-4 inhibitors remain an important established therapy segment, particularly because of their oral administration, established clinical use, and relatively favorable hypoglycemia profile.
• GLP-1 therapies are increasingly moving beyond traditional diabetes management, with cardiovascular and weight-management benefits expanding their therapeutic and commercial relevance.
• Dual GIP/GLP-1 therapies are reshaping the competitive landscape, with tirzepatide demonstrating the potential of multi-pathway incretin modulation.
• Oral administration represents a major commercial opportunity, particularly as advances in peptide delivery make oral GLP-1 therapies increasingly viable.
• Injectable therapies remain strategically important, particularly for high-value GLP-1 products and long-acting treatment regimens.
• Type 2 diabetes mellitus remains the primary indication, supported by the growing global burden of diabetes and the established role of incretin therapies in glycemic management.
• Obesity and weight management represents the most important incremental growth opportunity, as incretin therapies increasingly become part of chronic obesity-management strategies.
• Other metabolic disorders provide an emerging opportunity, with ongoing clinical development investigating incretin therapies across broader metabolic indications.
• Hospital pharmacies represent a major distribution channel, particularly for specialist-led treatment initiation and complex cardiometabolic patients.
• Retail pharmacies remain important for chronic maintenance therapy, especially for established oral products and repeat prescriptions.
• E-commerce is becoming increasingly relevant, particularly for direct-to-patient access and obesity-management therapies.
• Increasing prevalence of type 2 diabetes is the fundamental demand driver, creating a large and growing addressable patient population for incretin-based treatments.
• The shift toward non-insulin therapies is supporting adoption, as clinicians increasingly consider therapies that provide glycemic control alongside weight and cardiovascular benefits.
• Advancements in drug delivery technologies are expanding treatment accessibility, including oral peptide formulations, longer-acting therapies, and alternative delivery platforms.
• Cardiovascular and weight-management benefits are strengthening the value proposition of GLP-1 therapies, allowing manufacturers to address patient populations beyond conventional glucose-control pathways.
• Growing obesity prevalence is expanding the addressable market, particularly for GLP-1 and dual GIP/GLP-1 therapies.
• Patient preference for convenient administration is influencing product development, increasing interest in oral formulations, less frequent dosing, and simplified delivery devices.
• Combination therapies are emerging as a major innovation pathway, enabling simultaneous modulation of multiple metabolic pathways.
• Oral GLP-1 development could significantly change the competitive landscape, particularly by reducing injection-related barriers for patients.
• Microneedle patches and implantable drug-delivery systems represent emerging opportunities, although their commercial impact will depend on clinical validation, regulatory approval, and manufacturing scalability.
• High treatment costs remain a major restraint, particularly for branded GLP-1 therapies used for chronic obesity management.
• Reimbursement limitations can restrict access, especially where obesity treatment is not consistently covered by public or private health insurance.
• Adverse effects and contraindications may affect treatment persistence, with gastrointestinal intolerance representing an important consideration for GLP-1 therapies.
• Generic competition is increasing pressure on mature DPP-4 products, potentially improving affordability while reducing branded-product revenues.
• Supply availability is becoming an important competitive factor, particularly for high-demand GLP-1 therapies.
• Regulatory requirements remain significant, particularly for new formulations, expanded indications, combination therapies, and alternative delivery technologies.
• North America represents the largest regional market, supported by high treatment adoption, advanced healthcare infrastructure, specialist capacity, and strong commercialization of innovative metabolic therapies.
• The U.S. represents the principal North American market, with strong commercial activity around leading GLP-1 and dual GIP/GLP-1 products.
• Europe represents a mature but highly regulated market, where pricing, health technology assessment, and reimbursement decisions strongly influence product uptake.
Germany, the UK, France, Italy, Spain, and the Netherlands represent key European markets, with differences in reimbursement and obesity-treatment access shaping country-level adoption.
• Asia Pacific is projected to be the fastest-growing regional market, supported by the region’s substantial diabetes burden and increasing healthcare investment.
• China represents a major volume opportunity, although pricing pressure and local competition can influence the commercial potential of premium therapies.
• India offers significant long-term potential, driven by its large diabetes population, although affordability and limited reimbursement remain important barriers.
• Japan represents a mature metabolic-care market, where clinical positioning, reimbursement, and treatment convenience are likely to influence future growth.
• Australia and South Korea provide additional developed-market opportunities, particularly as coverage and access to obesity therapies expand.
• Latin America presents a growing but price-sensitive opportunity, with Brazil and Mexico representing important markets.
• The Middle East and Africa market remains comparatively smaller, but Saudi Arabia and the UAE provide attractive opportunities due to stronger healthcare infrastructure and purchasing power.
• Novo Nordisk is the leading market player, followed by major pharmaceutical companies including Eli Lilly, Takeda, Merck, Sanofi, AstraZeneca, Boehringer Ingelheim, Pfizer, and Teva Pharmaceuticals.
• The competitive landscape is increasingly centered on GLP-1 innovation, with companies competing through efficacy, dosing frequency, delivery format, safety, and expanded metabolic indications.
• Product lifecycle management is becoming increasingly important, with manufacturers pursuing new formulations and indications to extend commercial opportunities.
• Direct-to-patient distribution is emerging as an important commercial model, particularly for obesity therapies and self-administered medications.
• The market is increasingly separating into premium outcome-driven GLP-1 therapies and a more mature DPP-4 segment, with each serving different clinical and economic needs.
Key Company Profiles
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• GlaxoSmithKline
• Merck
• Novo Nordisk
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company
• Teva Pharmaceuticals
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
